We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.95B
1-Year Est. Return 773.9%
This Fund
S&P 500
This Quarter Est. Return
+13.35%
1 Year Est. Return
+773.9%
3 Year Est. Return
+3,976.92%
5 Year Est. Return
+17,750.67%
10 Year Est. Return
+592,782.78%
AUM
$2.6B
AUM Growth
-$20.1M
Cap. Flow
-$117M
Cap. Flow %
-4.48%
Top 10 Hldgs %
41.28%
Holding
99
New
18
Increased
10
Reduced
56
Closed
6

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$49.3M
2
ALXO icon
ALX Oncology
ALXO
+$38.2M
3
OMER icon
Omeros
OMER
+$28.6M
4
TRIL
Trillium Therapeutics Inc.
TRIL
+$24.9M
5
ZYME icon
Zymeworks
ZYME
+$20.6M

Top Sells

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$95.1M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$30.8M
3
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
+$23M
4
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$20.6M
5
CCXI
ChemoCentryx, Inc.
CCXI
+$16.2M

Sector Composition

Rank Sector Weight
1 Healthcare 87.13%
2 Miscellaneous 12.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXNX
26
DELISTED
Axonics, Inc. Common Stock
AXNX
$35.4M 1.36%
693,000
-27,397
-4% -$1.14M
AGEN
27
Agenus
AGEN
$321M
$34M 1.31%
433,075
-127,375
-23% -$9.91M
BHVN
28
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$32.5M 1.25%
500,000
-100,000
-17% -$6.55M
RCKT icon
29
Rocket Pharmaceuticals
RCKT
$382M
$31.3M 1.2%
1,368,550
-100,000
-7% -$2.46M
ARCT icon
30
Arcturus Therapeutics
ARCT
$448M
$30M 1.15%
700,000
-100,000
-13% -$4.96M
MYOV
31
DELISTED
Myovant Sciences Ltd.
MYOV
$30M 1.15%
2,134,966
-365,034
-15% -$6.79M
AKRO
32
DELISTED
Akero Therapeutics
AKRO
$26.5M 1.02%
859,550
+267,011
+45% +$9.33M
BPMC
33
DELISTED
Blueprint Medicines
BPMC
$25.5M 0.98%
275,000
-75,000
-21% -$5.78M
CRSP icon
34
CRISPR Therapeutics
CRSP
$5.11B
$25.1M 0.96%
300,000
-100,000
-25% -$8.87M
ALBO
35
DELISTED
Albireo Pharma Inc
ALBO
$23.4M 0.9%
+700,000
New +$20.4M
BNTX icon
36
BioNTech
BNTX
$24.3B
$22.4M 0.86%
325,000
+150,000
+86% +$10.8M
CABA icon
37
Cabaletta Bio
CABA
$437M
$22.4M 0.86%
2,067,302
-38,542
-2% -$443K
BEAM icon
38
Beam Therapeutics
BEAM
$2.38B
$19.6M 0.75%
796,428
-1
-0% -$25
ASND icon
39
Ascendis Pharma A/S
ASND
$16.2B
$19.3M 0.74%
125,000
-50,000
-29% -$7.19M
LKFT
40
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
$18.5M 0.71%
130,000
+30,925
+31% +$5.16M
AXSM icon
41
Axsome Therapeutics
AXSM
$11.1B
$17.8M 0.68%
250,000
-100,000
-29% -$7.79M
IGMS
42
DELISTED
IGM Biosciences
IGMS
$16.6M 0.64%
225,000
-115,146
-34% -$6.82M
ZLAB icon
43
Zai Lab
ZLAB
$2.83B
$15.7M 0.6%
189,092
-60,908
-24% -$4.89M
INSP icon
44
Inspire Medical Systems
INSP
$2.13B
$15.5M 0.6%
120,000
-27,982
-19% -$3.08M
KURA icon
45
Kura Oncology
KURA
$1B
$15.3M 0.59%
500,000
-200,000
-29% -$4.42M
CCXI
46
CALL
DELISTED
ChemoCentryx, Inc.
CCXI
$13.7M 0.53%
250,000
-750,000
-75% -$40.4M
PLRX icon
47
Pliant Therapeutics
PLRX
$70M
$13.6M 0.52%
611,409
– –
OTIC
48
DELISTED
Otonomy, Inc.
OTIC
$13.1M 0.5%
+3,241,800
New +$12.2M
DCPH
49
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$12.8M 0.49%
250,000
-68,914
-22% -$3.38M
TCRR
50
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$12.2M 0.47%
+600,000
New +$10.5M
1
2
3 4

Similar funds

AHC
Adell Harriman & Carpenter Houston, Texas $1.95B AUM 52.72% 1-Year Est. Return
FFS
Founders Financial Securities Towson, Maryland $1.95B AUM 22.17% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.95B AUM 25.88% 1-Year Est. Return
BFPW
BOK Financial Private Wealth Denver, Colorado $1.95B AUM 20.52% 1-Year Est. Return
MSA
MUFG Securities Americas New York $1.95B AUM 42.71% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Cormorant Asset Management's Q3 2020 Portfolio in Review

As of Q3 2020, Cormorant Asset Management held 99 positions worth $2.6B, down 0.77% from $2.62B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Cormorant Asset Management withdrew a net $117M in Q3 2020, closing 6 positions and reducing 56 holdings. Its most notable exit was Principia Biopharma Inc. Common Stock, an estimated $95.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 87% a quarter earlier, followed by Miscellaneous.

Against the trend, Cormorant Asset Management opened a new position in Immunovant worth $57.6M.

  • Cormorant Asset Management's largest Q3 2020 buy was Immunovant: 1,637,951 shares worth $57.6M.
  • Cormorant Asset Management added most to Omeros in Q3 2020, an estimated $28.6M increase.
  • Cormorant Asset Management's biggest Q3 2020 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $30.8M.
  • Cormorant Asset Management fully exited Principia Biopharma Inc. Common Stock in Q3 2020, selling an estimated $95.1M.
  • Cormorant Asset Management's ten largest holdings make up 41% of its $2.6B portfolio in Q3 2020.
  • Cormorant Asset Management opened 18 new positions and closed 6 in Q3 2020.
  • Cormorant Asset Management's portfolio value fell 0.77% quarter-over-quarter to $2.6B.

Based on Cormorant Asset Management's 13F filing for Q3 2020, filed 16 Nov 2020.